Antibody therapies could be a bridge to a coronavirus vaccine - but will the world benefit?

Ledford, Heidi

Ledford, Heidi.

Nature ; 584(7821): 333-334, 2020 08.

Article in English | MEDLINE | ID: covidwho-827564

Subject(s)

Antibodies, Monoclonal/economics; Antibodies, Monoclonal/therapeutic use; Antibodies, Neutralizing/economics; Antibodies, Neutralizing/therapeutic use; Coronavirus Infections/drug therapy; Coronavirus Infections/prevention & control; Pandemics/prevention & control; Pneumonia, Viral/drug therapy; Pneumonia, Viral/prevention & control; Antibodies, Monoclonal/biosynthesis; Antibodies, Monoclonal/immunology; Antibodies, Neutralizing/biosynthesis; Antibodies, Neutralizing/immunology; Bioreactors; COVID-19; COVID-19 Vaccines; Coronavirus Infections/immunology; Coronavirus Infections/therapy; Coronavirus Infections/virology; Humans; Immunization, Passive; Pneumonia, Viral/immunology; Pneumonia, Viral/virology; Randomized Controlled Trials as Topic; Time Factors; Viral Vaccines/immunology; Viral Vaccines/supply & distribution; COVID-19 Serotherapy

Keywords

Infection; Medical research; Policy; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Antibodies, Neutralizing / Pandemics / Antibodies, Monoclonal Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: Nature Year: 2020 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google